Skip to content

Group News

Aspen increases revenue from continuing operations by 12% to R37,8 billion

Sep 1, 2021

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to report the following salient financial results for the year ended 30 June 2021: Revenue from continuing operations increased by 12% to R37,8 billion (June 2020: R33,7 billion*);Normalised EBITDA from continuing operations increased by 3% to R9,9…

Read More >>

Stephen Saad discusses the J&J vaccine release with eNCA’s Sally Burdett

Jul 27, 2021

Aspen confirmed on 26 July 2021 that the first supplies to South Africa of the Johnson & Johnson COVID-19 vaccines, from the new API source located in Europe, were being released to Johnson & Johnson from its flagship Gqeberha-based manufacturing site. These vaccines will be further distributed throughout South Africa in line with the various…

Read More >>

Aspen confirms release of Covid-19 vaccines to Johnson & Johnson for supply to South Africa

Jul 26, 2021

Durban, South Africa – Aspen, a global multinational specialty pharmaceutical company, is pleased to confirm that the first supplies to South Africa of the Johnson & Johnson COVID-19 vaccines, from the new API source located in Europe, will be released to Johnson & Johnson from its flagship Gqeberha-based manufacturing site later today. These vaccines will…

Read More >>

CNN Live – Aspen’s US$700m investment in equitable vaccine access for Africa

Jul 8, 2021

“Over 90% of our vaccines are imported. A high majority from #India. When India cut off all exports, #Africa was left without vaccines.” Stephen Saad, CEO @aspenpharma discusses their recent $700M investment & ensuring future Africa supplies.

Read More >>

Aspen statement on manufacture and supply of COVID-19 vaccines

Jun 14, 2021

Durban – Aspen, a global multinational specialty pharmaceutical company, was extremely disappointed to learn over the past weekend that specific batches of the Johnson & Johnson COVID-19 vaccine manufactured at our Gqeberha production site and designated for the South African market have to be destroyed due to the Good Manufacturing Practice risk of isolated material…

Read More >>

Video: Presentation of Order of Merit to Stephen Saad by President Macron

May 31, 2021
Read More >>

French National Order of Merit conferred on Aspen’s Stephen Saad

May 28, 2021

Pretoria – The Chevalier de l’Ordre national du Mérite (Knight of the French National Order of Merit) was bestowed upon Stephen Saad, Aspen’s Group Chief Executive, at the University of Pretoria earlier today.  The national order, originally announced on 11 March 2019, was presented by President Emmanuel Macron at a small event with limited guests…

Read More >>

Aspen pledges its support for equitable vaccine access for Africa

May 28, 2021

Pretoria, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today participated in a high-level manufacturing seminar on manufacturing vaccines in Africa, hosted by South African President Cyril Ramaphosa and French President Emmanuel Macron.

Read More >>

Aspen Joins South Africa in Mourning Dr Sindi Van Zyl

Apr 11, 2021

Aspen joins the country and the medical fraternity in mourning the passing of Dr Sindi van Zyl, a dedicated and significant contributor to our country’s healthcare system. Dr Van Zyl will always be remembered for her ongoing involvement in helping our country in fighting the HIV/AIDS pandemic as a compassionate doctor and, an HIV clinician.…

Read More >>

VIDEOS – Stephen Saad’s address on the occasion of President Cyril Ramaphosa’s visit at our Sterile Facility in the Eastern Cape

Mar 29, 2021

Stephen Saad’s address on the occasion of President Cyril Ramaphosa’s visit at our Sterile Facility in the Eastern Cape at which time he announced the agreement reached with Johnson & Johnson to supply 250 million covid-19 vaccines to Africa, with 30 million being for South Africa

Read More >>

CONTACT DETAILS

Shauneen Beukes
Group Communications Manager
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Scroll To Top